Companies: 10,795·Total market cap: $144.5T
Arvinas, Inc.

Arvinas, Inc.

ARVNNASDAQHealthcare● Active
$7.52
+$0.10(+1.28%)
Market Cap$484876803
P/E Ratio
52W High$14.51
52W Low$6.06

Arvinas, Inc. (ARVN) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

arvn · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Arvinas, Inc. (ARVN) measures how much investors pay for each dollar of the company's trailing earnings. ARVN's current PE ratio of N/A is calculated by dividing its stock price of $7.51 by its TTM earnings per share of -$3.46.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-3.42
Based on 12 analysts
EPS (TTM)
-$3.46
TTM · diluted EPS
PEG Ratio
0.02
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Arvinas, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2016 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Arvinas, Inc.
Arvinas, Inc.You
ARVN
$485MN/A-$3.46
Astria Therapeutics, Inc.
Astria Therapeutics, Inc.
ATXS
$718MN/A-$1.68
ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc. Common Stock
AVBP
$1.4BN/A-$4.32
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc.
DAWN
$2.2BN/A-$1.04
Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc.
DNA
$536MN/A-$5.64
Erasca, Inc.
Erasca, Inc.
ERAS
$4.0BN/A-$0.44
Geron Corporation
Geron Corporation
GERN
$741MN/A-$0.13

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 10 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-1.24
2024-12-31
FY2024
$-2.77
2023-12-31
FY2023
$-6.62
2022-12-31
FY2022
$-5.31
2021-12-31
FY2021
$-3.82
2020-12-31
FY2020
$-3.02
2019-12-31
FY2019
$-2.13
2018-12-31
FY2018
$-1.31
2017-12-31
FY2017
$-1.16
2016-12-31
FY2016
$-7.56

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Arvinas, Inc. (ARVN) measures how much investors pay for each dollar of the company's trailing earnings. ARVN's current PE ratio of N/A is calculated by dividing its stock price of $7.51 by its TTM earnings per share of -$3.46.

PE Ratio = Stock Price ÷ EPS (TTM)
= $7.51 ÷ -$3.46 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

ARVN pe ratio · 6 questions

ARVN's current PE ratio is N/A as of 2026-06-08, based on a stock price of $7.51 and TTM EPS of -$3.46. Data sourced from Financial Modeling Prep via ARVN's SEC 10-K and 10-Q filings.

ARVN PE ratioWhat is ARVN PE ratioCurrent PE ratio of ARVNARVN PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Arvinas, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08